معرفی
Mark Douglas Chambers, MD is an Assistant Professor in the Department of Radiological Sciences at the University of California, Irvine School of Medicine. His research focuses on imaging biomarkers and antiangiogenic therapies in oncology, particularly in ovarian and peritoneal cancers. He has contributed to studies evaluating tumor blood flow via DCE-MRI as a predictor of treatment response to bevacizumab. His work explores the integration of imaging techniques with clinical outcomes to improve therapeutic strategies for recurrent cancers.
Dr. Chambers' research includes phase II clinical trials analyzing biomarkers such as circulating endothelial cells (CECs) and cytokines like IL-8 to predict treatment efficacy and prognosis. Collaborative studies with the Gynecologic Oncology Group and other institutions highlight his interest in combining targeted therapies (e.g., PARP inhibitors, VEGFR inhibitors) with immunotherapies for women's cancers.
His publications emphasize functional imaging endpoints and translational research, aiming to standardize techniques for assessing antiangiogenic activity and identifying predictive biomarkers in ovarian cancer.
